QGEN Nov 2019 30.000 call

OPR - OPR Delayed Price. Currency in USD
7.40
+0.58 (+8.50%)
As of 12:25PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close6.82
Open7.40
Bid10.00
Ask11.20
Strike30.00
Expire Date2019-11-15
Day's Range7.40 - 7.40
Contract RangeN/A
Volume10
Open InterestN/A
  • QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes
    Zacks

    QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes

    QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.

  • Barrons.com

    Dutch Diagnostics Group Qiagen Is Looking Like a Hot Acquisition And Shares Are Soaring

    Shares of Dutch genetic testing company Qiagen shot higher on Monday, after the company confirmed it had entered into discussions to “explore potential strategic alternatives” after receiving ”several nonbinding indications of interest.”

  • Reuters

    Qiagen shares surge as diagnostics group says open to takeover talks

    Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors. The shares had gained 14% on Wednesday, after a report that life sciences tools maker Thermo Fisher Scientific Inc had approached Qiagen about a potential deal. "The Supervisory Board and the Management Board ... are starting discussions with interested parties," the company said on Friday.

  • European stocks tread water after six winning weeks
    MarketWatch

    European stocks tread water after six winning weeks

    European stocks on Monday held on to levels they reached after six straight winning weeks, with most of the movement occurring in merger situations.

  • Reuters

    European shares extend winning streak; Qiagen jumps as company explores sale

    European shares edged closer to a record level on Monday, as optimism around U.S.-China trade talks and a surprise move by China's central bank in cutting a key interest rate painted an upbeat picture about global growth. The pan-European STOXX 600 index rose 0.17% by 0814 GMT, extending gains after its six-week winning streak. Also adding to the positive sentiment was news that China's central bank unexpectedly trimmed a closely watched lending rate for the first time in more than four years on Monday, a signal that policymakers are ready to act to prop up slowing growth.

  • Financial Times

    Qiagen/DNA: cell high

    Its Frankfurt-listed shares shot up in price on Monday after it confirmed reports of discussions with a number of suitors over a potential bid. Given Qiagen is already reasonably efficient, a deal at its current value would be tough to defend on cost grounds alone. There are a few medical technology groups sniffing around for deals.

  • Medtech Stock With 28% Gain This Week Confirms It's Fielding Buyout Bids
    Investor's Business Daily

    Medtech Stock With 28% Gain This Week Confirms It's Fielding Buyout Bids

    Dutch genetic-testing company Qiagen confirmed late Friday it's fielding several offers from potential suitors interested in acquiring it. Qiagen stock rose 8.8% on Friday.

  • Business Wire

    QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives

    QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company. The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties.

  • Reuters

    UPDATE 1-Qiagen exploring sale after indications of interest

    Qiagen NV said on Friday it has started reviewing options, including sale, after the genetic testing company received several indications of interest for acquisition, sending its U.S. listed shares up 8.5%. The company, which has a market capitalization of $8.6 billion as of Thursday's close, said its management will start talks with interested parties as part of the review. Instruments maker Thermo Fisher Scientific Inc approached Qiagen about a potential deal, Bloomberg reported on Wednesday.

  • ACCESSWIRE

    QIAGEN receives several conditional, non-binding indications of interest, and decides to enter into discussions to explore potential strategic alterna-tives

    VENLO, THE NETHERLANDS / ACCESSWIRE / November 15, 2019 / QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company. The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties.

  • Business Wire

    QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives

    QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company. The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties.

  • This Medtech Stock Jumped Bullishly On A Rumored $8 Billion Takeover
    Investor's Business Daily

    This Medtech Stock Jumped Bullishly On A Rumored $8 Billion Takeover

    Qiagen stock popped in bullish volume Thursday on a report medical technology giant Thermo Fisher Scientific could buy it for $8 billion. It would be one of Thermo Fisher's biggest buys.

  • Benzinga

    JPMorgan Upgrades Qiagen After Product Surveys, Valuation Analysis

    The swing to a bullish rating for Qiagen follows “our recent buy-side survey, two new product surveys, and valuation analysis,” Peterson said in the upgrade note. Barring this, there seems to be potential for the company’s new management team to reset the bar and capitalize on portfolio rationalization and cost reduction opportunities, Peterson mentioned.

  • MarketWatch

    Qiagen's stock extends surge after J.P. Morgan swings to bullish from bearish

    Shares of Qiagen N.V. surged 3.3% in premarket trading Thursday, after J.P. Morgan analyst Tycho Peterson swung to bullish from bearish on the Netherlands-based molecular testing company, citing expectations that company's turnaround will continue. The upgrade comes a day after the stock surged 9.9% after a Bloomberg report that Massachusetts-based analysis and diagnostics company Thermo Fisher Scientific Inc. was considering a buyout of Qiagen, which had a market capitalization of $8.03 billion as of Wednesday's close. J.P. Morgan's Peterson upgraded Qiagen to overweight from underweight and boosted his price target to $40 from $25. "Barring a near-term takeout..., we see potential for new management to reset the bar and pursue abundant opportunities for portfolio rationalization and cost reduction, and therefore we think the worst is in the rearview for [Qiagen]," Peterson wrote in a note to clients. The stock has run up 40% since closing at a 3-year low on Oct. 8 through Wednesday, while the S&P 500 has gained 6.9% over the same time.

  • QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%
    Zacks

    QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%

    QIAGEN (QGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

  • Thermo Fisher Considers Buying $8 Billion Diagnostics Firm Qiagen
    Bloomberg

    Thermo Fisher Considers Buying $8 Billion Diagnostics Firm Qiagen

    (Bloomberg) -- Qiagen NV shares jumped the most in 17 years after people with knowledge of the matter said Thermo Fisher Scientific Inc. is considering a takeover of the molecular testing firm.Thermo Fisher has approached the Dutch company about a potential purchase that could become one of its biggest-ever acquisitions, the people said, asking not to be identified because the information is private. Shares of Qiagen rose 13% to 33.20 euros at 1:10 p.m. in Frankfurt, giving it a market value of $8.3 billion. There’s no certainty the deliberations will lead to a transaction, and other bidders for Qiagen could emerge, the people said. Thermo Fisher shares rose 1.4% to $300.02 at the close of New York trading on Wednesday, valuing it at more than $120 billion.The potential transaction could become one of Thermo Fisher’s largest purchases, surpassing its $5 billion takeover of drug-ingredient maker Patheon NV in 2017, according to data compiled by Bloomberg. Its largest acquisition was its $15 billion purchase of Life Technologies Corp. in 2014, the data show.Deal PipelineQiagen spokesman Thomas Theuringer declined to comment, citing company policy. The company serves doctors, researchers and others with molecular-testing platforms that can extract and analyze people’s DNA and RNA. The company emerged from university research and has grown in recent years amid the boom in genetic testing.Representatives for Thermo Fisher, based in Waltham, Massachusetts, couldn’t immediately comment.U.K. scientific measurement testing company LGC Group also has attracted sale interest. The private equity firm Cinven has teamed up with the Abu Dhabi Investment Authority to weigh a joint bid for the KKR & Co.-backed company, people familiar with the matter have said.Leadership ChangeThermo Fisher Chief Executive Officer Marc Casper told analysts last month he feels “great” about the company’s mergers and acquisitions pipeline, which “continues to be very active.”Qiagen CEO Peer Schatz announced last month that he will step down after 27 years at the company, saying it’s time to bring in new leadership. Senior Vice President Thierry Bernard will act as interim CEO until a permanent successor is found. The company also cut its quarterly estimate for sales growth, sending its shares plunging the most in 17 years.Top medical device makers have the capacity to take on additional debt to finance acquisitions, according to Bloomberg Intelligence. Last year, Thermo Fisher rival Medtronic Plc agreed to buy the shares it doesn’t already own in Mazor Robotics Ltd. in a deal valuing the company at about $1.6 billion.(Updates share move in first two paragraphs.)\--With assistance from Aaron Kirchfeld and Tim Loh.To contact the reporters on this story: Ed Hammond in New York at ehammond12@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net;Nabila Ahmed in New York at nahmed54@bloomberg.netTo contact the editors responsible for this story: Ben Scent at bscent@bloomberg.net, ;Liana Baker at lbaker75@bloomberg.net, Eric PfannerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • European stocks edge lower on China trade concerns and ‘worst of all worlds’ German economic data
    MarketWatch

    European stocks edge lower on China trade concerns and ‘worst of all worlds’ German economic data

    European stocks slipped on Thursday on concern over the state of U.S.-China trade talks as data showed a stagnating economy in Germany.

  • TheStreet.com

    [video]Qiagen Jumps on Report Thermo Fisher Is Considering a Bid

    Qiagen rises following a report that says Thermo Fisher Scientific is considering a purchase of the Dutch molecular-testing company.

  • GlobeNewswire

    HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Qiagen (QGEN) Investors with Significant Losses to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud

    SAN FRANCISCO, Nov. 13, 2019 -- Hagens Berman urges Qiagen N.V. (NYSE: QGEN) investors who have suffered significant losses to submit their losses now or contact the firm.

  • GlobeNewswire

    EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of QIAGEN N.V.

    NEW YORK, Nov. 12, 2019 -- Levi & Korsinsky reminds investors that it has commenced an investigation of QIAGEN N.V. (“QIAGEN” or “the Company”) (NYSE: QGEN) concerning.

  • Business Wire

    ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against QIAGEN N.V. – QGEN

    Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V. resulting from allegations that Qiagen may have issued materially misleading business information to the investing public.

  • GlobeNewswire

    EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of QIAGEN N.V.

    NEW YORK,, Nov. 06, 2019 -- Levi & Korsinsky reminds investors that it has commenced an investigation of QIAGEN N.V. (“QIAGEN” or “the Company”) (NYSE: QGEN) concerning.

  • Business Wire

    QIAGEN Launches Novel NGS Workflow for Simultaneous DNA and RNA Analysis for Use in Cancer Profiling at 2019 AMP Annual Meeting

    HILDEN, Germany & GERMANTOWN, Md.-- -- QIAseq ® Multimodal Panels streamline simultaneous DNA and RNA sequencing for comprehensive solid and liquid tumor profiling Only solution to extract, enrich and sequence DNA variants and RNA fusions and assess gene expression in a single workflow from a single sample within a single day QIAGEN to highlight extensive Sample to Insight portfolio for clinical laboratories ...

  • Business Wire

    QIAGEN Expands Portfolio of Immuno-Oncology Assets for Future Companion Diagnostics and Biomarkers

    HILDEN, Germany & GERMANTOWN, Md.-- -- Collaborates with Repertoire Genesis for access to T-cell /B-cell receptor repertoire assays for clinical next-generation sequencing Acquires licensing rights for epigenomic immune checkpoint inhibitor biomarkers developed by researchers from the University of Bonn Receives exclusive license to novel mRNA gene expression signatures from STRATIFYER Molecular Pathology ...